Literature DB >> 10463378

Treatment of alcohol withdrawal syndrome with gabapentin.

U Bonnet1, M Banger, F M Leweke, M Maschke, T Kowalski, M Gastpar.   

Abstract

Four in-patients with moderate alcohol-withdrawal syndromes benefited from treatment with gabapentin administered in an add-on fashion to clomethiazole. In comparison with the amount of clomethiazole required as estimated using a specially developed score during previous detoxifications of these patients at our hospital, gabapentin (400 mg q.i.d.) clearly reduced the amount of clomethiazole needed now Gabapentin, an anticonvulsant with favorable pharmacokinetic properties and tolerability, and with no known risk of dependence, may therefore be a useful new drug in the treatment of alcohol withdrawal. We believe that the potential value of gabapentin in alcohol withdrawal deserves further controlled studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10463378     DOI: 10.1055/s-2007-979203

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  25 in total

1.  Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients.

Authors:  Maher Karam-Hage; Kirk J Brower
Journal:  Psychiatry Clin Neurosci       Date:  2003-10       Impact factor: 5.188

2.  Psychiatric Uses of Newer Anticonvulsants.

Authors:  Timothy R. Berigan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-04

Review 3.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Update on the neurobiology of alcohol withdrawal seizures.

Authors:  Michael A Rogawski
Journal:  Epilepsy Curr       Date:  2005 Nov-Dec       Impact factor: 7.500

5.  Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat.

Authors:  Serena Stopponi; Lorenzo Somaini; Andrea Cippitelli; Giordano de Guglielmo; Marsida Kallupi; Nazzareno Cannella; Gilberto Gerra; Maurizio Massi; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-02       Impact factor: 4.530

6.  Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.

Authors:  Joseph P Schacht; Patrick K Randall; L R Waid; Alicia M Baros; Patricia K Latham; Tara M Wright; Hugh Myrick; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2011-06-01       Impact factor: 3.455

Review 7.  Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date.

Authors:  Mary R Lee; Lorenzo Leggio
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 8.  Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.

Authors:  Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

9.  Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics.

Authors:  Joseph P Schacht; Raymond F Anton; Patrick K Randall; Xingbao Li; Scott Henderson; Hugh Myrick
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 10.  Recent advances in the pharmacotherapy of alcoholism.

Authors:  Hugh Myrick; Raymond Anton
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.